The PRAC recommendations will now be forwarded to the Committee for Medicinal Products for Human Use, which will adopt the Agency’s final opinion and provide clear guidance to patients and healthcare professionals. A final EU decision is therefore awaited, and MHRA guidance may be issued in due course.